文献速递类风湿关节炎

certolizumab pegol联合csDMARDs治疗RA达标后停用csDMARDs的开放标签随机对照试验

An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

本研究纳入活动性RA患者,在certolizumab pegol联合csDMARDs治疗3或6个月达到DAS28改善≥1.2后,随机分为继续联合治疗组或停用csDMARDs组。18个月时两组维持ΔDAS28≥1.2或达到DAS28低疾病活动度的比例分别为72%和69%,但未满足非劣效性假设(绝对风险差上限90%CI:2.6%(19.1%))。结论:停用csDMARDs未证明非劣效于继续联合治疗,但两组改善均持续至18个月。

要点

  • RA患者经certolizumab pegol联合csDMARDs达标后停用csDMARDs未达到非劣效性。
  • 18个月时继续联合组与单药组疗效指标无统计学差异,改善均持续。
  • 研究为非劣效性设计未达成,提示维持联合治疗可能更稳妥。

核心结论

  • 在certolizumab pegol联合csDMARDs治疗达到疗效反应的RA患者中,停用csDMARDs未证明非劣效于继续联合治疗,但两组改善在18个月时均持续。

研究设计与样本

  • 开放标签随机对照试验,纳入活动性RA患者,在certolizumab pegol联合现有csDMARDs治疗3或6个月达到ΔDAS28≥1.2后随机分组。
  • 共入组125例,88例随机至继续联合治疗组(COMBO,n=43)或停用csDMARDs组(MONO,n=45)。
  • 主要结局为18个月时维持ΔDAS28≥1.2或达到DAS28低疾病活动度的非劣效性,非劣效界值为15个百分点。

主要发现

  • 18个月时ΔDAS28≥1.2和/或达到DAS28低疾病活动度的比例两组分别为72%和69%,但非劣效性假设未满足(绝对风险差上限90%CI:2.6%(19.1%))。
  • DAS28基线校正改善值COMBO组-2.3 vs MONO组-2.1,P=0.49。
  • 达到DAS28低疾病活动度比例59% vs 56%,ΔDAS28≥1.2比例69% vs 59%,缓解比例均为41%,所有终点均无统计学差异。
  • 两组基线年龄、性别、种族、RF状态或既往生物制剂使用(16% vs 11%)无显著差异。

关键数值与推荐

  • 非劣效界值:15个百分点。
  • 主要结局非劣效性未达成:绝对风险差上限90%CI为2.6%(19.1%)。

临床怎么用

  • 对于certolizumab pegol联合csDMARDs治疗达标的RA患者,停用csDMARDs未证明非劣效,临床决策维持联合治疗可能更稳妥。
  • 两组18个月疗效指标无显著差异,个体化评估后可考虑继续联合治疗。

局限性

  • 开放标签设计,未设盲。
  • 样本量较小,随机分组仅88例。
  • 非劣效性假设未满足,不能排除停用csDMARDs的劣效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objective of this trial was to compare effectiveness of certolizumab pegol added to conventional synthetic DMARDs (csDMARDs) in RA patients, followed by continuing vs discontinuing background csDMARDs after treatment response. METHODS: Patients with active RA who had certolizumab pegol added to their existing csDMARD regimen due to inadequate response were eligible. At 3 or 6 months, patients who achieved a change (Δ) in DAS28 of ⩾1.2 were randomized to continue combination therapy (COMBO) or withdraw csDMARD therapy (MONO) (unblinded). The primary outcome was non-inferiority of stopping vs continuing csDMARD(s) in terms of maintaining ΔDAS28 ⩾ 1.2 or achieving DAS28 low disease activity at 18 months (non-inferiority margin: 15 percentile units). RESULTS: A total of 125 patients were enrolled, 88 randomized to COMBO (n = 43) or MONO (n = 45). No significant differences were observed between groups in baseline age, gender, race, RF status or prior biologics (16% vs 11%). Although the rate of ΔDAS28 ⩾ 1.2 and/or DAS28 low disease activity achievement at 18 months was clinically comparable between the two groups (72% vs 69%), non-inferiority assumptions were not met [absolute risk difference (upper limit of 90% CI): 2.6% (19.1%)]. Similar baseline-adjusted improvements were seen in DAS28 (COMBO vs MONO: -2.3 vs -2.1; P = 0.49) and all endpoints were not statistically different including 59% vs 56% achieved DAS28 low disease activity, 69% vs 59% ΔDAS28 ⩾ 1.2, and 41% each remission. CONCLUSION: Among RA patients achieving a therapeutic response on combination therapy with certolizumab pegol and csDMARDs, withdrawing csDMARDs was not non-inferior to maintaining csDMARDs but improvements were sustained in both groups at 18 months.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Pope J, Rampakakis E, Vaillancourt J, et al. An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs. Rheumatology (Oxford). 2020. PMID: 31628486. doi:10.1093/rheumatology/kez470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。